Blood Biomarkers for the Management of Mild Traumatic Brain Injury in Clinical Practice.
Charlotte OrisSamy KahouadjiDamien BouvierVincent SapinPublished in: Clinical chemistry (2024)
In adults, the inclusion of S100B in Scandinavian and French guidelines has reduced the need for CT scans by at least 30%. S100B has significant potential as a diagnostic biomarker, but limitations include its rapid half-life, which requires blood collection within 3 h of trauma, and its lack of neurospecificity. In 2018, the FDA approved the use of combined determination of GFAP and UCH-L1 to aid in the assessment of mTBI. Since 2022, new French guidelines also recommend the determination of GFAP and UCH-L1 in order to target a larger number of patients (sampling within 12 h post-injury) and optimize the reduction of CT scans. In the future, new cut-offs related to age and promising new biomarkers are expected for both diagnostic and prognostic applications.
Keyphrases
- clinical practice
- mild traumatic brain injury
- computed tomography
- dual energy
- contrast enhanced
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- positron emission tomography
- magnetic resonance imaging
- molecularly imprinted
- current status
- patient reported outcomes
- risk assessment
- patient reported
- mass spectrometry
- quantum dots
- climate change
- sensitive detection
- clinical evaluation